Bessemer Group’s Meridian Bioscience Inc VIVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-129
| Closed | -$4K | – | 2122 |
|
|
2022
Q4 | $4K | Hold |
129
| – | – | ﹤0.01% | 1701 |
|
|
2022
Q3 | $4K | Sell |
129
-30
| -19% | -$971 | ﹤0.01% | 1824 |
|
|
2022
Q2 | $5K | Hold |
159
| – | – | ﹤0.01% | 1555 |
|
|
2022
Q1 | $4K | Buy |
+159
| New | +$3.78K | ﹤0.01% | 1651 |
|
|
2020
Q3 | – | Sell |
-606
| Closed | -$14K | – | 1742 |
|
|
2020
Q2 | $14K | Buy |
+606
| New | +$8.78K | ﹤0.01% | 1500 |
|
|
2020
Q1 | – | Sell |
-57,900
| Closed | -$566K | – | 1745 |
|
|
2019
Q4 | $566K | Sell |
57,900
-68,600
| -54% | -$644K | ﹤0.01% | 884 |
|
|
2019
Q3 | $1.2M | Buy |
126,500
+70,600
| +126% | +$744K | ﹤0.01% | 655 |
|
|
2019
Q2 | $664K | Sell |
55,900
-60,800
| -52% | -$732K | ﹤0.01% | 806 |
|
|
2019
Q1 | $2.06M | Buy |
116,700
+32,800
| +39% | +$546K | 0.01% | 447 |
|
|
2018
Q4 | $1.46M | Buy |
83,900
+20,100
| +32% | +$343K | 0.01% | 483 |
|
|
2018
Q3 | $951K | Hold |
63,800
| – | – | ﹤0.01% | 590 |
|
|
2018
Q2 | $1.01M | Hold |
63,800
| – | – | ﹤0.01% | 568 |
|
|
2018
Q1 | $906K | Buy |
63,800
+44,500
| +231% | +$659K | ﹤0.01% | 607 |
|
|
2017
Q4 | $270K | Buy |
+19,300
| New | +$283K | ﹤0.01% | 958 |
|
|
2017
Q1 | – | Sell |
-78,800
| Closed | -$1.4M | – | 1951 |
|
|
2016
Q4 | $1.4M | Buy |
78,800
+9,800
| +14% | +$172K | 0.01% | 623 |
|
|
2016
Q3 | $1.33M | Buy |
+69,000
| New | +$1.35M | 0.01% | 545 |
|
Other funds holding VIVO
Bessemer Group's VIVO Position: Q1 2023 in Review
Bessemer Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 129 shares — an estimated $4K sold.
Bessemer Group first reported a position in VIVO in Q3 2016 and held it in 16 quarters. The position peaked at $2.06M in Q1 2019. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.
- Bessemer Group reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
- Bessemer Group sold 129 Meridian Bioscience Inc shares in Q1 2023, an estimated $4K.
- Bessemer Group first reported a position in Meridian Bioscience Inc in Q3 2016 and held it in 16 quarters.
- Bessemer Group's Meridian Bioscience Inc position peaked at $2.06M in Q1 2019.
- 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.
Based on Bessemer Group's 13F filing for Q1 2023, filed 10 May 2023.